NR4A1 and breast carcinoma: In the context of breast cancer, which involves the use of anti-estrogen agents and aromatase inhibitors in hormone receptor-positive cases, AKR1C1, AKR1C2, and AKR1C3 have been found to be upregulated in tamoxifen-resistant breast cancer cells.